Clinical Trials Browser

Completed × HER2-positive Breast Cancer × pertuzumab × Clear all

NCT07115095 2025-08-11

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Phase NA Completed

HER2-positive Breast Cancer

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Phase 3 Completed

214 enrolled 16 charts

HER2-positive Breast Cancer